Premium
ICD Trials: An Extraordinary Means of Determining Patient Risk?
Author(s) -
NISAM SEAH,
MOWER MORTON
Publication year - 1998
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.1998.tb00203.x
Subject(s) - medicine , implantable cardioverter defibrillator , sudden cardiac death , intensive care medicine , randomized controlled trial , clinical trial , sudden death , medical emergency
Extensive clinical experience with the implantable cardioverter defibrillator (ICD) combined with recently completed prospective, randomized trials like MADIT and AVID, have demonstrated the lifesaving efficacy of this therapy and its superiority compared to conventional medical management in treating patients at high risk of sudden arrhythmic death. This evidence has in turn spurred great interest in further ICD studies. Since the ability of the ICD to save lives is no longer in question, there is a need to reexamine the real objectives of these new studies.